Immune system Dysregulation in uremia: Role of oxidative stress

被引:70
作者
Descamps-Latscha, B [1 ]
Jungers, P [1 ]
Witko-Sarsat, V [1 ]
机构
[1] Hop Necker Enfants Malad, INSERM, U507, F-75015 Paris, France
关键词
immune dysregulation; inflammation; oxidative stress; chronic renal failure; hemodialysis; advanced oxidation protein products;
D O I
10.1159/000063558
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immune system dysregulation in end-stage renal disease patients is a multifactorial process combining profound immunodeficiency with a state of cellular activation. While at the origin of the deficiency uremic toxins are thought to play a prominent role, the dialysis procedure is the main factor for the genesis of a recurrent cellular activation process leading to a chronic inflammation state dominated by oxidative stress and its related severe complications, e.g. beta(2)-microglobulin amyloid arthropathy and accelerated atherosclerosis. The recent identification of advanced oxidation protein products (AOPPs) in the plasma of uremic patients and the following demonstration that AOPPs act as both potential uremic toxins and proinflammatory mediators, have opened novel areas of research on these novel molecular bases of oxidative stress and on therapeutic strategies aimed at reducing its most deleterious effects in hemodialysis patients. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 22 条
  • [1] Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure
    CeballosPicot, I
    WitkoSarsat, V
    MeradBoudia, M
    Nguyen, AT
    Thevenin, M
    Jaudon, MC
    Zingraff, J
    Verger, C
    Jungers, P
    DescampsLatscha, B
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1996, 21 (06) : 845 - 853
  • [2] Impairment of antioxidant defense mechanisms in elderly women without increase in oxidative stress markers: "A weak equilibrium"
    Cristol, JP
    Abderrazick, M
    Favier, F
    Michel, F
    Castel, J
    Leger, C
    Descomps, B
    [J]. LIPIDS, 1999, 34 : S289 - S289
  • [3] Descamps-Latscha B, 2001, KIDNEY INT, V59, pS108
  • [4] Descamps-Latscha B, 1993, Curr Opin Nephrol Hypertens, V2, P883, DOI 10.1097/00041552-199311000-00005
  • [5] Dialysis-induced oxidative stress:: Biological aspects, clinical consequences, and therapy
    Descamps-Latscha, B
    Drüeke, T
    Witko-Sarsat, V
    [J]. SEMINARS IN DIALYSIS, 2001, 14 (03) : 193 - 199
  • [6] DESCAMPSLATSCHA B, 1994, SEMIN NEPHROL, V14, P253
  • [7] DESCAMPSLATSCHA B, 1995, J IMMUNOL, V154, P882
  • [8] DESCAMPSLATSCHA B, 1996, REPLACEMENT RENAL FU, P45
  • [9] CYTOKINES - AGENTS-PROVOCATEURS IN HEMODIALYSIS
    DINARELLO, CA
    HARRINGTON, JT
    KING, A
    KASSIRER, JP
    LEVEY, AS
    MEYER, K
    KURTIN, P
    GELFAND, J
    PEREIRA, BJG
    SINGH, A
    [J]. KIDNEY INTERNATIONAL, 1992, 41 (03) : 683 - 694
  • [10] Dinarello CA, 2001, ANN RHEUM DIS, V60, pIII18